[
    {
        "interaction_id":1,
        "drug_a":"Warfarin",
        "drug_b":"Ibuprofen",
        "severity":"Major",
        "mechanism":"Pharmacodynamic (additive antiplatelet effect) & Pharmacokinetic (GI irritation)",
        "clinical_effect":"Significantly increased risk of gastrointestinal bleeding and bruising.",
        "safer_alternative":"Acetaminophen (Paracetamol)"
    },
    {
        "interaction_id":2,
        "drug_a":"Simvastatin",
        "drug_b":"Clarithromycin",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Clarithromycin is a potent CYP3A4 inhibitor, dramatically reducing the metabolism of Simvastatin.",
        "clinical_effect":"Increased simvastatin exposure leading to a significantly elevated risk of myopathy and rhabdomyolysis.",
        "safer_alternative":"Azithromycin or Amoxicillin"
    },
    {
        "interaction_id":3,
        "drug_a":"Sertraline",
        "drug_b":"Tramadol",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Both drugs increase serotonin activity. Tramadol also inhibits serotonin reuptake.",
        "clinical_effect":"Increased risk of serotonin syndrome (symptoms: agitation, confusion, tachycardia, hyperthermia, muscle rigidity).",
        "safer_alternative":"Morphine or Oxycodone (with caution)"
    },
    {
        "interaction_id":4,
        "drug_a":"Clopidogrel",
        "drug_b":"Omeprazole",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Omeprazole inhibits CYP2C19, the enzyme required to convert clopidogrel into its active metabolite.",
        "clinical_effect":"Reduced antiplatelet effect of clopidogrel, potentially increasing the risk of cardiovascular events like stent thrombosis.",
        "safer_alternative":"Pantoprazole or Famotidine"
    },
    {
        "interaction_id":5,
        "drug_a":"Digoxin",
        "drug_b":"Verapamil",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Verapamil inhibits P-glycoprotein, reducing the renal clearance of digoxin.",
        "clinical_effect":"Increased digoxin serum levels, leading to a high risk of toxicity (nausea, vomiting, dizziness, cardiac arrhythmias).",
        "safer_alternative":"Amlodipine"
    },
    {
        "interaction_id":6,
        "drug_a":"Spironolactone",
        "drug_b":"Potassium Supplement",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Additive potassium-sparing effects.",
        "clinical_effect":"Severe hyperkalemia, which can lead to life-threatening cardiac arrhythmias.",
        "safer_alternative":"Loop Diuretic (e.g., Furosemide)"
    },
    {
        "interaction_id":7,
        "drug_a":"Lithium",
        "drug_b":"Ibuprofen",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: NSAIDs reduce renal blood flow and inhibit prostaglandin synthesis, leading to decreased renal clearance of lithium.",
        "clinical_effect":"Increased lithium serum levels, resulting in lithium toxicity (nausea, tremor, confusion, ataxia, renal damage).",
        "safer_alternative":"Acetaminophen"
    },
    {
        "interaction_id":8,
        "drug_a":"Methotrexate",
        "drug_b":"Trimethoprim\/Sulfamethoxazole",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Both drugs are antifolate agents. Pharmacokinetic: Possible competition for renal secretion.",
        "clinical_effect":"Additive myelosuppression (neutropenia, thrombocytopenia) and increased risk of pancytopenia and methotrexate toxicity.",
        "safer_alternative":"Pentamidine (for PJP prophylaxis)"
    },
    {
        "interaction_id":9,
        "drug_a":"Sildenafil",
        "drug_b":"Nitroglycerin",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Both drugs cause vasodilation and potentiate hypotensive effects.",
        "clinical_effect":"Profound hypotension, syncope, myocardial infarction, or stroke.",
        "safer_alternative":"Alternative angina treatment (e.g., Ranolazine)"
    },
    {
        "interaction_id":10,
        "drug_a":"Phenytoin",
        "drug_b":"Ciprofloxacin",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Ciprofloxacin may inhibit the metabolism of phenytoin, and phenytoin may increase the metabolism of ciprofloxacin.",
        "clinical_effect":"Increased phenytoin levels (risk of toxicity: nystagmus, ataxia, drowsiness) and decreased ciprofloxacin levels (risk of therapeutic failure).",
        "safer_alternative":"Levofloxacin"
    },
    {
        "interaction_id":11,
        "drug_a":"Warfarin",
        "drug_b":"Fluconazole",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Fluconazole inhibits CYP2C9, the primary enzyme responsible for warfarin metabolism.",
        "clinical_effect":"Significantly increased warfarin levels and anticoagulant effect, leading to a high risk of bleeding.",
        "safer_alternative":"Terbinafine (oral) or topical antifungal"
    },
    {
        "interaction_id":12,
        "drug_a":"Valproic Acid",
        "drug_b":"Lamotrigine",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Valproic acid inhibits the glucuronidation of lamotrigine, reducing its clearance.",
        "clinical_effect":"Doubling or more of lamotrigine serum levels, dramatically increasing the risk of serious skin rashes, including Stevens-Johnson syndrome and toxic epidermal necrolysis.",
        "safer_alternative":"Levetiracetam"
    },
    {
        "interaction_id":13,
        "drug_a":"Cyclosporine",
        "drug_b":"St. John's Wort",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: St. John's Wort is a potent inducer of CYP3A4 and P-glycoprotein, increasing the metabolism and clearance of cyclosporine.",
        "clinical_effect":"Dramatically reduced cyclosporine levels, leading to subtherapeutic immunosuppression and high risk of organ rejection in transplant patients.",
        "safer_alternative":"Avoid all herbal supplements"
    },
    {
        "interaction_id":14,
        "drug_a":"Theophylline",
        "drug_b":"Ciprofloxacin",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Ciprofloxacin inhibits CYP1A2, the main enzyme responsible for theophylline metabolism.",
        "clinical_effect":"Markedly increased theophylline serum concentrations, leading to toxicity (nausea, vomiting, seizures, cardiac arrhythmias).",
        "safer_alternative":"Levofloxacin or Ceftriaxone"
    },
    {
        "interaction_id":15,
        "drug_a":"Rifampin",
        "drug_b":"Warfarin",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Rifampin is a potent inducer of CYP2C9 and other enzymes, dramatically increasing the metabolism of warfarin.",
        "clinical_effect":"Greatly reduced warfarin effect, leading to subtherapeutic anticoagulation and risk of thrombosis.",
        "safer_alternative":"Alternative antibiotic if possible (e.g., Doxycycline)"
    },
    {
        "interaction_id":16,
        "drug_a":"Codeine",
        "drug_b":"Paroxetine",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Paroxetine is a strong CYP2D6 inhibitor. Codeine is a prodrug that requires CYP2D6 to be converted into its active form, morphine.",
        "clinical_effect":"Greatly reduced analgesic efficacy of codeine due to impaired conversion to morphine.",
        "safer_alternative":"Morphine"
    },
    {
        "interaction_id":17,
        "drug_a":"Allopurinol",
        "drug_b":"Azathioprine",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Allopurinol inhibits xanthine oxidase (XO), the enzyme that metabolizes azathioprine to its inactive metabolites.",
        "clinical_effect":"Dramatically increased levels of azathioprine and its active metabolites, leading to severe myelosuppression (pancytopenia) and increased risk of infection.",
        "safer_alternative":"Febuxostat (with extreme caution and dose adjustment of azathioprine)"
    },
    {
        "interaction_id":18,
        "drug_a":"Linezolid",
        "drug_b":"Sertraline",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Linezolid is a weak, reversible monoamine oxidase inhibitor (MAOI). Sertraline is a serotonin reuptake inhibitor (SSRI).",
        "clinical_effect":"Increased risk of serotonin syndrome.",
        "safer_alternative":"Vancomycin"
    },
    {
        "interaction_id":19,
        "drug_a":"Diltiazem",
        "drug_b":"Metoprolol",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Additive effects on cardiac conduction (SA and AV node) and contractility.",
        "clinical_effect":"Increased risk of bradycardia, AV block, and hypotension.",
        "safer_alternative":"Amlodipine (with metoprolol)"
    },
    {
        "interaction_id":20,
        "drug_a":"Warfarin",
        "drug_b":"Acetaminophen",
        "severity":"Moderate",
        "mechanism":"Unclear; may involve inhibition of warfarin metabolism or reduction of vitamin K-dependent clotting factors.",
        "clinical_effect":"Increased anticoagulant effect and risk of bleeding, especially with regular use of high doses (>2g per day).",
        "safer_alternative":"Use lowest effective dose"
    },
    {
        "interaction_id":21,
        "drug_a":"Levothyroxine",
        "drug_b":"Calcium Carbonate",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Calcium binds to levothyroxine in the GI tract, forming an insoluble complex that reduces absorption.",
        "clinical_effect":"Reduced levothyroxine absorption, leading to decreased efficacy and symptoms of hypothyroidism.",
        "safer_alternative":"Space administration by 4 hours"
    },
    {
        "interaction_id":22,
        "drug_a":"Digoxin",
        "drug_b":"Furosemide",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Furosemide can cause hypokalemia and hypomagnesemia, which sensitize the myocardium to the effects of digoxin.",
        "clinical_effect":"Increased risk of digoxin toxicity (arrhythmias, nausea, vomiting) even at therapeutic digoxin levels.",
        "safer_alternative":"Monitor electrolytes closely"
    },
    {
        "interaction_id":23,
        "drug_a":"Olanzapine",
        "drug_b":"Diazepam",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Additive CNS depression.",
        "clinical_effect":"Increased risk of excessive sedation, drowsiness, respiratory depression, and impaired motor skills.",
        "safer_alternative":"Use lower doses and monitor"
    },
    {
        "interaction_id":24,
        "drug_a":"Ethinyl Estradiol",
        "drug_b":"Carbamazepine",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Carbamazepine is a potent inducer of CYP3A4, which increases the metabolism of estrogen.",
        "clinical_effect":"Significantly reduced contraceptive efficacy, leading to unplanned pregnancy and breakthrough bleeding.",
        "safer_alternative":"Non-hormonal IUD or higher-dose OC"
    },
    {
        "interaction_id":25,
        "drug_a":"Warfarin",
        "drug_b":"Amiodarone",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Amiodarone inhibits CYP2C9, the primary enzyme responsible for warfarin metabolism.",
        "clinical_effect":"Markedly increased warfarin effect and risk of bleeding.",
        "safer_alternative":"Reduce warfarin dose proactively"
    },
    {
        "interaction_id":26,
        "drug_a":"Atorvastatin",
        "drug_b":"Itraconazole",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Itraconazole is a potent CYP3A4 inhibitor, reducing the metabolism of atorvastatin.",
        "clinical_effect":"Increased atorvastatin exposure, elevating the risk of myopathy and rhabdomyolysis.",
        "safer_alternative":"Pravastatin or Rosuvastatin"
    },
    {
        "interaction_id":27,
        "drug_a":"Metformin",
        "drug_b":"Cimetidine",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Cimetidine may compete with metformin for renal tubular secretion, potentially reducing its clearance.",
        "clinical_effect":"Increased metformin levels, potentially increasing the risk of lactic acidosis.",
        "safer_alternative":"Famotidine or Ranitidine"
    },
    {
        "interaction_id":28,
        "drug_a":"Quetiapine",
        "drug_b":"Phenytoin",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Phenytoin is a potent inducer of CYP3A4, which is primarily responsible for quetiapine metabolism.",
        "clinical_effect":"Dramatically reduced quetiapine levels, leading to loss of efficacy in treating psychiatric symptoms.",
        "safer_alternative":"Valproic Acid"
    },
    {
        "interaction_id":29,
        "drug_a":"Sildenafil",
        "drug_b":"Alpha-blockers (e.g., Doxazosin)",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Additive vasodilatory effects, leading to hypotension.",
        "clinical_effect":"Symptomatic hypotension, dizziness, syncope.",
        "safer_alternative":"Tamsulosin"
    },
    {
        "interaction_id":30,
        "drug_a":"Warfarin",
        "drug_b":"Vitamin K",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Vitamin K is a cofactor for the synthesis of clotting factors that warfarin inhibits. It directly antagonizes warfarin's effect.",
        "clinical_effect":"Reduced anticoagulant effect of warfarin, increasing risk of thrombosis.",
        "safer_alternative":"Consistent dietary intake"
    },
    {
        "interaction_id":31,
        "drug_a":"Ciprofloxacin",
        "drug_b":"Calcium Carbonate",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Divalent cations (Ca2+) chelate ciprofloxacin in the GI tract, forming an insoluble complex that reduces absorption.",
        "clinical_effect":"Significantly reduced antibiotic absorption, leading to potential therapeutic failure.",
        "safer_alternative":"Space administration by 2-4 hours"
    },
    {
        "interaction_id":32,
        "drug_a":"Levothyroxine",
        "drug_b":"Proton Pump Inhibitors (e.g., Omeprazole)",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: PPIs increase gastric pH, which may impair the dissolution and absorption of levothyroxine tablets.",
        "clinical_effect":"Decreased levothyroxine efficacy, requiring dose increase.",
        "safer_alternative":"Consider liquid levothyroxine formulation"
    },
    {
        "interaction_id":33,
        "drug_a":"Duloxetine",
        "drug_b":"Aspirin",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Both drugs increase the risk of bleeding via different mechanisms (SSRI effect on platelets + antiplatelet effect of aspirin).",
        "clinical_effect":"Increased risk of bleeding, particularly GI bleeding.",
        "safer_alternative":"Acetaminophen for pain"
    },
    {
        "interaction_id":34,
        "drug_a":"Metoprolol",
        "drug_b":"Diphenhydramine",
        "severity":"Minor",
        "mechanism":"Pharmacodynamic: Additive sedative effects.",
        "clinical_effect":"Increased drowsiness and fatigue.",
        "safer_alternative":"Loratadine or Cetirizine (2nd-gen antihistamines)"
    },
    {
        "interaction_id":35,
        "drug_a":"Warfarin",
        "drug_b":"Ginkgo Biloba",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Ginkgo biloba has antiplatelet properties.",
        "clinical_effect":"Increased risk of bleeding.",
        "safer_alternative":"Avoid herbal supplement"
    },
    {
        "interaction_id":36,
        "drug_a":"Sertraline",
        "drug_b":"Tamsulosin",
        "severity":"Minor",
        "mechanism":"Pharmacodynamic: Sertraline can inhibit CYP2D6, potentially increasing tamsulosin levels slightly.",
        "clinical_effect":"Potential for increased incidence of dizziness or orthostatic hypotension.",
        "safer_alternative":"Monitor for dizziness"
    },
    {
        "interaction_id":37,
        "drug_a":"Furosemide",
        "drug_b":"Ibuprofen",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: NSAIDs inhibit prostaglandin-mediated renal vasodilation, reducing the diuretic and antihypertensive efficacy of furosemide.",
        "clinical_effect":"Fluid retention, edema, and reduced blood pressure control.",
        "safer_alternative":"Acetaminophen"
    },
    {
        "interaction_id":38,
        "drug_a":"Citalopram",
        "drug_b":"Tramadol",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Increased serotonergic activity. Pharmacokinetic: CYP2D6 inhibition by citalopram may impair tramadol activation.",
        "clinical_effect":"Increased risk of serotonin syndrome and reduced analgesic efficacy of tramadol.",
        "safer_alternative":"Morphine"
    },
    {
        "interaction_id":39,
        "drug_a":"Insulin",
        "drug_b":"Beta-Blockers (e.g., Propranolol)",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Beta-blockers can mask tachycardia, a key symptom of hypoglycemia, and may impair glycogenolysis.",
        "clinical_effect":"Masked hypoglycemia symptoms, increased risk of severe hypoglycemia.",
        "safer_alternative":"Cardioselective beta-blocker (e.g., Atenolol, Metoprolol)"
    },
    {
        "interaction_id":40,
        "drug_a":"Digoxin",
        "drug_b":"Hawthorn",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Additive effects on cardiac conduction and contractility.",
        "clinical_effect":"Potential for increased risk of bradycardia and digoxin toxicity.",
        "safer_alternative":"Avoid herbal supplement"
    },
    {
        "interaction_id":41,
        "drug_a":"Venlafaxine",
        "drug_b":"Ketoconazole",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Ketoconazole inhibits CYP3A4, which metabolizes venlafaxine to a lesser extent. It primarily inhibits CYP2D6, affecting the active metabolite.",
        "clinical_effect":"Increased venlafaxine and desvenlafaxine levels, potentially increasing side effects (hypertension, nausea, serotonin syndrome risk).",
        "safer_alternative":"Terbinafine"
    },
    {
        "interaction_id":42,
        "drug_a":"Phenytoin",
        "drug_b":"Warfarin",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Complex. Phenytoin can induce CYP2C9, increasing warfarin metabolism. It may also displace warfarin from protein binding sites.",
        "clinical_effect":"Unpredictable effect on INR; may increase or decrease warfarin effect.",
        "safer_alternative":"Monitor INR very closely"
    },
    {
        "interaction_id":43,
        "drug_a":"Diazepam",
        "drug_b":"Cimetidine",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Cimetidine inhibits CYP3A4 and CYP2C19, impairing the metabolism of diazepam.",
        "clinical_effect":"Increased diazepam levels, leading to prolonged sedation and CNS depression.",
        "safer_alternative":"Famotidine or Ranitidine"
    },
    {
        "interaction_id":44,
        "drug_a":"Lithium",
        "drug_b":"ACE Inhibitors (e.g., Lisinopril)",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: ACE inhibitors can reduce renal clearance of lithium by altering sodium balance.",
        "clinical_effect":"Increased lithium levels and risk of toxicity.",
        "safer_alternative":"Calcium Channel Blocker (e.g., Amlodipine)"
    },
    {
        "interaction_id":45,
        "drug_a":"Sildenafil",
        "drug_b":"Erythromycin",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Erythromycin inhibits CYP3A4, the primary metabolizing enzyme for sildenafil.",
        "clinical_effect":"Increased sildenafil levels, increasing the risk of side effects (hypotension, flushing, priapism).",
        "safer_alternative":"Azithromycin"
    },
    {
        "interaction_id":46,
        "drug_a":"Metronidazole",
        "drug_b":"Ethanol",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Disulfiram-like reaction. Metronidazole inhibits aldehyde dehydrogenase.",
        "clinical_effect":"Acetaldehyde accumulation causing nausea, vomiting, flushing, tachycardia, and hypotension.",
        "safer_alternative":"Abstain from alcohol"
    },
    {
        "interaction_id":47,
        "drug_a":"Tetracycline",
        "drug_b":"Ferrous Sulfate",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Divalent cations (Fe2+) chelate tetracycline in the GI tract, forming an insoluble complex.",
        "clinical_effect":"Markedly reduced absorption of both tetracycline and iron, leading to therapeutic failure for both.",
        "safer_alternative":"Space administration by 2-4 hours"
    },
    {
        "interaction_id":48,
        "drug_a":"Bupropion",
        "drug_b":"Ritonavir",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Ritonavir may induce the metabolism of bupropion via CYP2B6.",
        "clinical_effect":"Reduced bupropion levels and efficacy.",
        "safer_alternative":"Monitor for decreased efficacy"
    },
    {
        "interaction_id":49,
        "drug_a":"Olanzapine",
        "drug_b":"Carbamazepine",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Carbamazepine is a potent inducer of CYP1A2, which metabolizes olanzapine.",
        "clinical_effect":"Dramatically reduced olanzapine levels, leading to loss of antipsychotic efficacy.",
        "safer_alternative":"Valproic Acid"
    },
    {
        "interaction_id":50,
        "drug_a":"Warfarin",
        "drug_b":"Saw Palmetto",
        "severity":"Minor",
        "mechanism":"Theoretical pharmacodynamic: Potential antiplatelet effects.",
        "clinical_effect":"Potential increased risk of bleeding, though evidence is weak.",
        "safer_alternative":"Avoid herbal supplement"
    },
    {
        "interaction_id":51,
        "drug_a":"Levothyroxine",
        "drug_b":"Soy Protein",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Soy can bind to levothyroxine and impair its absorption.",
        "clinical_effect":"Decreased levothyroxine absorption and efficacy.",
        "safer_alternative":"Space administration by 4 hours"
    },
    {
        "interaction_id":52,
        "drug_a":"Paroxetine",
        "drug_b":"Tamoxifen",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Paroxetine is a strong CYP2D6 inhibitor. Tamoxifen is a prodrug requiring CYP2D6 for conversion to its active metabolite, endoxifen.",
        "clinical_effect":"Drastically reduced endoxifen levels, significantly increasing the risk of breast cancer recurrence.",
        "safer_alternative":"Venlafaxine or Citalopram"
    },
    {
        "interaction_id":53,
        "drug_a":"Diltiazem",
        "drug_b":"Sildenafil",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Additive vasodilatory effects. Pharmacokinetic: Diltiazem may inhibit CYP3A4, increasing sildenafil levels.",
        "clinical_effect":"Increased risk of hypotension, dizziness, and flushing.",
        "safer_alternative":"Use lower sildenafil dose (25mg)"
    },
    {
        "interaction_id":54,
        "drug_a":"Metformin",
        "drug_b":"Contrast Dye (Iodinated)",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Contrast dye can impair renal function, reducing metformin clearance and increasing the risk of lactic acidosis.",
        "clinical_effect":"Increased risk of metformin-associated lactic acidosis.",
        "safer_alternative":"Withhold metformin"
    },
    {
        "interaction_id":55,
        "drug_a":"Amitriptyline",
        "drug_b":"Alcohol",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Additive CNS depression.",
        "clinical_effect":"Severely impaired motor skills, dizziness, and increased risk of overdose.",
        "safer_alternative":"Avoid alcohol"
    },
    {
        "interaction_id":56,
        "drug_a":"Furosemide",
        "drug_b":"Gentamicin",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Both drugs are ototoxic and nephrotoxic. Furosemide can cause volume depletion, exacerbating gentamicin toxicity.",
        "clinical_effect":"Increased risk of irreversible hearing loss and acute kidney injury.",
        "safer_alternative":"Monitor levels and function closely"
    },
    {
        "interaction_id":57,
        "drug_a":"Carbamazepine",
        "drug_b":"Doxycycline",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Carbamazepine induces CYP3A4, increasing the metabolism of doxycycline.",
        "clinical_effect":"Reduced doxycycline levels and antibiotic efficacy.",
        "safer_alternative":"Increase doxycycline dose or use alternative antibiotic"
    },
    {
        "interaction_id":58,
        "drug_a":"Warfarin",
        "drug_b":"Green Tea",
        "severity":"Minor",
        "mechanism":"Pharmacodynamic: Green tea contains vitamin K, which can antagonize warfarin's effect.",
        "clinical_effect":"Reduced INR and anticoagulant effect.",
        "safer_alternative":"Consistent dietary intake"
    },
    {
        "interaction_id":59,
        "drug_a":"Insulin",
        "drug_b":"Thiazide Diuretics (e.g., HCTZ)",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Thiazides can cause hypokalemia and hyperglycemia.",
        "clinical_effect":"Worsened glycemic control, requiring an increase in insulin dose.",
        "safer_alternative":"Monitor blood glucose closely"
    },
    {
        "interaction_id":60,
        "drug_a":"Celecoxib",
        "drug_b":"Fluconazole",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Fluconazole inhibits CYP2C9, the primary enzyme responsible for celecoxib metabolism.",
        "clinical_effect":"Increased celecoxib levels, increasing the risk of GI bleeding and cardiovascular events.",
        "safer_alternative":"Acetaminophen or a non-CYP2C9 metabolized NSAID"
    },
    {
        "interaction_id":61,
        "drug_a":"Digoxin",
        "drug_b":"Macrolides (e.g., Clarithromycin)",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Macrolides may inhibit P-glycoprotein and alter gut flora that metabolize digoxin, increasing its absorption.",
        "clinical_effect":"Increased digoxin levels and risk of toxicity.",
        "safer_alternative":"Azithromycin"
    },
    {
        "interaction_id":62,
        "drug_a":"Phenobarbital",
        "drug_b":"Oral Contraceptives",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Phenobarbital is a potent inducer of CYP3A4, increasing the metabolism of estrogen and progestin.",
        "clinical_effect":"Significantly reduced contraceptive hormone levels, leading to contraceptive failure.",
        "safer_alternative":"Non-hormonal IUD or higher-dose OC"
    },
    {
        "interaction_id":63,
        "drug_a":"Quetiapine",
        "drug_b":"Hydrocodone",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Additive CNS depression.",
        "clinical_effect":"Increased sedation, dizziness, and impaired mental alertness.",
        "safer_alternative":"Monitor closely for sedation"
    },
    {
        "interaction_id":64,
        "drug_a":"Warfarin",
        "drug_b":"Dronedarone",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Dronedarone inhibits CYP2C9, reducing the metabolism of warfarin.",
        "clinical_effect":"Increased warfarin levels and risk of bleeding.",
        "safer_alternative":"Reduce warfarin dose by 50%"
    },
    {
        "interaction_id":65,
        "drug_a":"Sertraline",
        "drug_b":"Sumatriptan",
        "severity":"Moderate",
        "mechanism":"Pharmacodynamic: Theoretical increased serotonergic activity.",
        "clinical_effect":"Theoretical increased risk of serotonin syndrome.",
        "safer_alternative":"Monitor for serotonin syndrome"
    },
    {
        "interaction_id":66,
        "drug_a":"Metronidazole",
        "drug_b":"Lithium",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Mechanism unclear; may reduce renal clearance of lithium.",
        "clinical_effect":"Increased lithium levels and risk of toxicity.",
        "safer_alternative":"Alternative antibiotic (e.g., Clindamycin)"
    },
    {
        "interaction_id":67,
        "drug_a":"Atorvastatin",
        "drug_b":"Grapefruit Juice",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Compounds in grapefruit juice inhibit intestinal CYP3A4, reducing the first-pass metabolism of atorvastatin.",
        "clinical_effect":"Markedly increased atorvastatin absorption and exposure, significantly increasing the risk of myopathy.",
        "safer_alternative":"Avoid grapefruit juice"
    },
    {
        "interaction_id":68,
        "drug_a":"Venlafaxine",
        "drug_b":"Methadone",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Venlafaxine may inhibit CYP2D6, potentially affecting methadone metabolism. Pharmacodynamic: Additive QTc prolongation risk.",
        "clinical_effect":"Potential for increased methadone levels and increased risk of QTc prolongation.",
        "safer_alternative":"Monitor QTc interval"
    },
    {
        "interaction_id":69,
        "drug_a":"Warfarin",
        "drug_b":"Fish Oil (Omega-3)",
        "severity":"Minor",
        "mechanism":"Pharmacodynamic: High doses of fish oil may have mild antiplatelet effects.",
        "clinical_effect":"Theoretical increased risk of bleeding.",
        "safer_alternative":"Use with caution and monitor INR"
    },
    {
        "interaction_id":70,
        "drug_a":"Citalopram",
        "drug_b":"Carvedilol",
        "severity":"Minor",
        "mechanism":"Pharmacokinetic: Citalopram is a weak CYP2D6 inhibitor. Carvedilol is metabolized by CYP2D6.",
        "clinical_effect":"Potential for a slight increase in carvedilol levels and effects (bradycardia, hypotension).",
        "safer_alternative":"Monitor heart rate and BP"
    },
    {
        "interaction_id":71,
        "drug_a":"Spironolactone",
        "drug_b":"Digoxin",
        "severity":"Minor",
        "mechanism":"Pharmacokinetic: Spironolactone may slightly reduce the renal clearance of digoxin.",
        "clinical_effect":"Slight increase in digoxin levels.",
        "safer_alternative":"Monitor digoxin levels"
    },
    {
        "interaction_id":72,
        "drug_a":"Omeprazole",
        "drug_b":"Clozapine",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Omeprazole may inhibit CYP2C19 and CYP1A2, potentially increasing clozapine levels.",
        "clinical_effect":"Increased risk of clozapine toxicity (sedation, seizures, myocarditis).",
        "safer_alternative":"Pantoprazole"
    },
    {
        "interaction_id":73,
        "drug_a":"Warfarin",
        "drug_b":"Cranberry Juice",
        "severity":"Minor",
        "mechanism":"Pharmacodynamic: Case reports suggest potential for increased anticoagulant effect; mechanism unclear.",
        "clinical_effect":"Potential to increase INR and risk of bleeding.",
        "safer_alternative":"Avoid large or concentrated amounts"
    },
    {
        "interaction_id":74,
        "drug_a":"Metformin",
        "drug_b":"Cephalexin",
        "severity":"Minor",
        "mechanism":"Pharmacokinetic: Cephalexin may compete with metformin for renal tubular secretion.",
        "clinical_effect":"Theoretical minor increase in metformin levels.",
        "safer_alternative":"Monitor"
    },
    {
        "interaction_id":75,
        "drug_a":"Dextromethorphan",
        "drug_b":"Quinidine",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Quinidine inhibits CYP2D6, dramatically reducing the metabolism of dextromethorphan.",
        "clinical_effect":"Greatly increased dextromethorphan levels, leading to serotonin syndrome and CNS side effects.",
        "safer_alternative":"Guaifenesin"
    },
    {
        "interaction_id":76,
        "drug_a":"Levothyroxine",
        "drug_b":"Aluminum Hydroxide (Antacid)",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Aluminum binds to levothyroxine in the GI tract, reducing absorption.",
        "clinical_effect":"Reduced levothyroxine efficacy.",
        "safer_alternative":"Space administration by 4 hours"
    },
    {
        "interaction_id":77,
        "drug_a":"Risperidone",
        "drug_b":"Carbamazepine",
        "severity":"Major",
        "mechanism":"Pharmacokinetic: Carbamazepine induces CYP3A4, which metabolizes risperidone to its active metabolite. It also induces UGT and P-gp.",
        "clinical_effect":"Complex; may alter the ratio of risperidone to its metabolite and reduce total active moiety levels, potentially reducing efficacy.",
        "safer_alternative":"Valproic Acid"
    },
    {
        "interaction_id":78,
        "drug_a":"Warfarin",
        "drug_b":"Aspirin",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Additive antiplatelet effects and GI irritation.",
        "clinical_effect":"Significantly increased risk of major bleeding, especially gastrointestinal bleeding.",
        "safer_alternative":"Use only if strong indication exists (e.g., mechanical heart valve)"
    },
    {
        "interaction_id":79,
        "drug_a":"Sildenafil",
        "drug_b":"Alpha-Blockers (e.g., Doxazosin)",
        "severity":"Major",
        "mechanism":"Pharmacodynamic: Additive vasodilatory effects, leading to hypotension.",
        "clinical_effect":"Symptomatic hypotension, dizziness, syncope.",
        "safer_alternative":"Tamsulosin"
    },
    {
        "interaction_id":80,
        "drug_a":"Fluoxetine",
        "drug_b":"Risperidone",
        "severity":"Moderate",
        "mechanism":"Pharmacokinetic: Fluoxetine and its metabolite norfluoxetine are potent CYP2D6 inhibitors, reducing the metabolism of risperidone to its active metabolite.",
        "clinical_effect":"Increased risperidone levels and decreased 9-hydroxyrisperidone levels, potentially increasing the risk of side effects (extrapyramidal symptoms, sedation).",
        "safer_alternative":"Sertraline or Citalopram"
    }
]